Donate

Take Action

For the past 20 years, we have worked hard to make sure everyone with a bleeding disorders has access to affordable life-saving treatment. One of the ways we do this is to support legislation like the Patient’s Access to Treatment Act (HR 460). This bill would prohibit an insurance company from charging more for drugs placed on specialty tiers than they do for drugs placed on their non-preferred brand tiers. The passage of HR 460 is vital to keep medication affordable for all living with chronic conditions.

Recently, the Immune Deficiency Foundation (IDF) – one of the organizations we work closely with – started a Change.org petition to encourage the passage of HR 460.

Click here to join the thousands of people that support HR 460 and sign it today

Tier.300What are Specialty Tiers?

Patients with chronic and expensive conditions like a bleeding disorder, are disproportionately impacted by a shift in cost-share when their clotting factor is placed into specialty tiers.

These tiers often forgo the traditional model of charging patients a copay, and instead charge a percentage of the cost through co-insurance. When clotting factor is placed in a specialty tier, the cost of co-insruance for the patient can range from 20% to 50%!

Learn more by reading our specialty tier toolkit. 

Facebook Comments

Sign up for E-mails, Dateline Newsletter, and other ways to stay connected.